Adding quizartinib (Daiichi Sankyo) to standard chemotherapy and consolidation significantly improves overall survival (OS) in adults with newly diagnosed FLT3 internal tandem duplication–positive (ITD+) acute myeloid leukemia (AML), according to a new study. These results come from the phase 3 QUANTUM-First trial reported at the 2022 annual meeting of the European Hematology Association (abstract S100).
“I believe quizartinib in combination with intensive chemotherapy with three
JULY 13, 2022